Physician profile
Andrew Chernick
NPI 1386628469
$7,840.67
in general payments reported to CMS, 2019-2025
31 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $497 · 2021: $520 · 2022: $1,264 · 2023: $1,751 · 2024: $1,485 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,605 · Education: $36.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,605.10 |
| Education | $36.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,997.33 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $742.07 | 2019-2023 | Trulance, Xifaxan |
| Pfizer INC. | $658.04 | 2019-2025 | |
| Janssen Biotech, INC. | $582.29 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $520.11 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $391.53 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $244.91 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $164.76 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $152.24 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $148.91 | 2025 | Watchman Flx |
| Daiichi Sankyo INC. | $146.98 | 2019-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $115.94 | 2019-2023 | Linzess |
| Qol Medical, LLC | $113.98 | 2019-2025 | Sucraid |
| Evoke Pharma, INC. | $96.71 | 2023 | Gimoti |
| Nestle Healthcare Nutrition INC. | $95.80 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $88.95 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $84.96 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $75.30 | 2019-2024 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $75.24 | 2020-2023 | Dificid |
| Aimmune Therapeutics, INC. | $54.41 | 2023-2024 | |
| Ardelyx, INC. | $53.89 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $42.48 | 2025 | Vegzelma |
| Redhill Biopharma INC. | $41.00 | 2022 | |
| Amgen INC. | $36.00 | 2023-2025 | Avsola, Amjevita, Uplizna |
| Alfasigma USA, INC. | $25.57 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.15 | 2023 | Cyltezo |
| Ucb, INC. | $16.05 | 2019 | |
| Fresenius Kabi USA, LLC | $15.09 | 2023 | |
| Intercept Pharmaceuticals, INC. | $14.67 | 2020 | |
| Shire North American Group INC | $14.00 | 2019 | |
| Allergan, INC. | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Chernick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.